Open tíbia Fracture

2

Review clinical trials related to Open tíbia Fracture. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinical status six months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) injury-related amputation of the lower extremity, 3) unplanned reoperation to manage wound complications, infection, or delayed fracture healing, and 4) clinical fracture healing as assessed using the Functional IndeX for Trauma (FIX-IT) instrument. The secondary outcomes will independently assess the four components of the primary outcome. This is a Phase III trial.

Participants needed: 312
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: University of Maryland, BaltimoreUpdated: May 5, 2026Locations: 34
Eligibility criteria

Patients 18 years of age or older. [+5]

Due to the severity of injury, the treating surgeon does not believe limb salvag... [+11]

Status: Recruiting

Intramedullary Calcium Sulfate Antibiotic Depot

The goal of this randomized clinical trial is to study the best treatment for open lower leg fractures to prevent infection. The main questions it aims to answer is if treating tibia fracture patients with a calcium sulfate antibiotic depot is better at preventing infection that the standard of care.

Participants needed: 497
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Wake Forest University Health SciencesUpdated: Dec 15, 2025Locations: 10
Eligibility criteria

Patients 18 years and older [+1]

Less than 18 years of age [+6]